Literature DB >> 6466517

Alterations in angina threshold with nifedipine during pacing induced angina.

P H Kramer, K Chatterjee, A Schwartz, K Swedberg, J L Rouleau, D Curran, L Blevins, W W Parmley.   

Abstract

Changes in coronary haemodynamics and angina threshold were determined during atrial pacing in 11 patients with fixed obstructive coronary artery disease with effort angina before and after the administration of 20 mg of oral nifedipine. Coronary vascular resistance decreased at resting and at "subangina" heart rates but not at "angina" rates. Primary coronary vasodilatation with nifedipine was also suggested by higher coronary sinus oxygen content whether at rest or at subangina or angina heart rates. After nifedipine angina occurred at a lower double product and lower myocardial oxygen consumption. These findings suggest that nifedipine is a coronary vasodilator, but angina can occur at a lower angina threshold in some patients with obstructive coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6466517      PMCID: PMC481630          DOI: 10.1136/hrt.52.3.308

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  20 in total

1.  Measurement of coronary sinus blood flow by continuous thermodilution in man.

Authors:  W Ganz; K Tamura; H S Marcus; R Donoso; S Yoshida; H J Swan
Journal:  Circulation       Date:  1971-08       Impact factor: 29.690

2.  Beneficial enhancement of coronary blood flow by nifedipine. Comparison with nitroglycerin and beta blocking agents.

Authors:  H J Engel; P R Lichtlen
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

3.  Coronary sinus reflux. A source of error in the measurement of thermodilution coronary sinus flow.

Authors:  D G Mathey; K Chatterjee; J V Tyberg; J Lekven; B Brundage; W W Parmley
Journal:  Circulation       Date:  1978-04       Impact factor: 29.690

4.  Production of ischaemic cardiac pain by nifedipine.

Authors:  A G Jariwalla; E G Anderson
Journal:  Br Med J       Date:  1978-05-06

Review 5.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.

Authors:  P H Stone; E M Antman; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

6.  Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease.

Authors:  G Bergman; K Daly; L Atkinson; M Rothman; P J Richardson; G Jackson; D E Jewitt
Journal:  Lancet       Date:  1981-03-14       Impact factor: 79.321

7.  Mechanisms of angina relief after nifedipine: a hemodynamic and myocardial metabolic study.

Authors:  H Emanuelsson; S Holmberg
Journal:  Circulation       Date:  1983-07       Impact factor: 29.690

8.  Mechanism of relief of pacing induced angina with oral verapamil: reduced oxygen demand.

Authors:  J L Rouleau; K Chatterjee; T A Ports; M B Doyle; B Hiramatsu; W W Parmley
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

9.  Nifedipine therapy for Prinzmetal's angina.

Authors:  J E Muller; S J Gunther
Journal:  Circulation       Date:  1978-01       Impact factor: 29.690

10.  Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin.

Authors:  T Mann; P F Cohn; L B Holman; L H Green; J E Markis; D A Phillips
Journal:  Circulation       Date:  1978-04       Impact factor: 29.690

View more
  2 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.